Treatment of unexplained coma and hypokinetic-rigid syndrome in a patient with COVID-19.
BMJ Case Rep
; 14(3)2021 Mar 02.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1115107
ABSTRACT
The COVID-19 pandemic has dealt a devastating blow to healthcare systems globally. Approximately 3.2% of patients infected with COVID-19 require invasive ventilation during the course of the illness. Within this population, 25% of patients are affected with neurological manifestations. Among those who are affected by severe neurological manifestations, some may have acute cerebrovascular complications (5%), impaired consciousness (15%) or exhibit skeletal muscle hypokinesis (20%). The cause of the severe cognitive impairment and hypokinesis is unknown at this time. Potential causes include COVID-19 viral encephalopathy, toxic metabolic encephalopathy, post-intensive care unit syndrome and cerebrovascular pathology. We present a case of a 60 year old patient who sustained a prolonged hospitalization with COVID-19, had a cerebrovascular event and developed a persistent unexplained encephalopathy along with a hypokinetic state. He was treated successfully with modafinil and carbidopa/levodopa showing clinical improvement within 3-7 days and ultimately was able to successfully discharge home.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Rehabilitación
/
Encefalopatías
/
Carbidopa
/
Levodopa
/
Hipocinesia
/
Modafinilo
/
Accidente Cerebrovascular Isquémico
/
SARS-CoV-2
/
COVID-19
Tipo de estudio:
Reporte de caso
/
Estudios diagnósticos
/
Estudio pronóstico
Tópicos:
Covid persistente
Límite:
Humanos
/
Masculino
/
Middle aged
Idioma:
Inglés
Año:
2021
Tipo del documento:
Artículo
País de afiliación:
Bcr-2020-239781
Similares
MEDLINE
...
LILACS
LIS